X4 Pharmaceuticals (XFOR) Non-Current Deffered Revenue (2017 - 2025)
X4 Pharmaceuticals posted quarterly Non-Current Deffered Revenue of $621000.0 for Q4 2025, down 21.29% on a QoQ basis from $789000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) has 3 years of Non-Current Deffered Revenue data on file, last reported at $621000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $621000.0; the trailing twelve-month figure through Dec 2025 stood at $621000.0 (changed N/A YoY), and the FY2025 full-year result was $621000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $621000.0, down from $789000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $955000.0 in Q1 2025 and bottomed at $621000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | 621,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 621,000.00 |
| Sep 30, 2025 | 789,000.00 |
| Jun 30, 2025 | 827,000.00 |
| Mar 31, 2025 | 955,000.00 |
| Dec 31, 2018 | 417,000.00 |
| Sep 30, 2018 | 1.32 Mn |
| Jun 30, 2018 | 1.52 Mn |
| Mar 31, 2018 | 1.80 Mn |
| Dec 31, 2017 | 1.94 Mn |